5HT3 Antagonism and Auditory Gating in Schizophrenia

This study has been completed.

First Received: July 3, 2001 Last Updated: January 20, 2009 History of Changes

Sponsor:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00018850

Purpose

The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Another purpose of this study is to determine how the altered brain functioning in schizophrenia contributes the symptoms found in the illness.

Condition	Intervention
Schizophrenia	Drug: ondansetron Behavioral: neuropsychological testing Drug: nicotine Drug: haloperidol

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacokinetics Study
Official Title:	5HT3 Antagonism and Auditory Gating in Schizophrenia

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia

Drug Information available for: Serotonin Haloperidol Nicotine tartrate Haloperidol decanoate Haloperidol lactate Nicotine polacrilex Ondansetron hydrochloride Ondansetron

U.S. FDA Resources

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	June 1998
Estimated Study Completion Date:	June 2003

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Subjects with diagnosed with schizophrenia will be studied.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018850

Locations

United States, Colorado
VAMC
Denver, Colorado, United States, 80013

Sponsors and Collaborators

Department of Veterans Affairs

More Information

No publications provided

Study ID Numbers:	MHBS-013-99F
Study First Received:	July 3, 2001
Last Updated:	January 20, 2009
ClinicalTrials.gov Identifier:	NCT00018850 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by Department of Veterans Affairs:

schizophrenia
ondansetron
nicotine
haloperidol

Additional relevant MeSH terms:

Neurotransmitter Agents
Cholinergic Agonists
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Nicotinic Agonists
Physiological Effects of Drugs
Psychotropic Drugs
Antiemetics
Cholinergic Agents
Haloperidol
Schizophrenia
Serotonin Antagonists
Nicotine
Mental Disorders
Therapeutic Uses

Ganglionic Stimulants
Antipruritics
Ondansetron
Dermatologic Agents
Schizophrenia and Disorders with Psychotic Features
Tranquilizing Agents
Gastrointestinal Agents
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents
Pharmacologic Actions
Haloperidol decanoate
Serotonin Agents
Autonomic Agents
Anti-Anxiety Agents

ClinicalTrials.gov processed this record on February 08, 2010